Patient-reported problems filling buprenorphine prescriptions and motivations for illicit use
- PMID: 36844166
- PMCID: PMC9949336
- DOI: 10.1016/j.dadr.2022.100091
Patient-reported problems filling buprenorphine prescriptions and motivations for illicit use
Abstract
Background: While barriers to accessing buprenorphine (BUP) therapy have been well described, little is known about pharmacy-related barriers. The objective of this study was to estimate the prevalence of patient-reported problems filling BUP prescriptions and determine whether these problems were associated with illicit use of BUP. The secondary objectives included identifying motivations for illicit BUP use and the prevalence of naloxone acquisition among patients prescribed BUP.
Methods: Between July 2019 and March 2020, 139 participants receiving treatment for an opioid use disorder (OUD) at two sites within a rurally-located health system, completed an anonymous 33-item survey. A multivariable model was used to assess the association between pharmacy-related problems filling BUP prescriptions and illicit substance use.
Results: More than a third of participants reported having problems filling their BUP prescription (34.1%, n = 47) with the most commonly reported problems being insufficient pharmacy stock of BUP (37.8%, n = 17), pharmacist refusal to dispense BUP (37.8%, n = 17), and insurance problems (34.0%, n = 16). Of those who reported illicit BUP use (41.5%, n = 56), the most common motivations were to avoid/ease withdrawal symptoms (n = 39), prevent/reduce cravings (n = 39), maintain abstinence (n = 30), and treat pain (n = 19). In the multivariable model, participants who reported a pharmacy-related problems were significantly more likely to use illicitly obtained BUP (OR=8.93, 95% CI: 3.12, 25.52, p < 0.0001).
Conclusion: Efforts to improve BUP access have primarily focused on increasing the number of clinicians waivered to prescribe; however, challenges persist with BUP dispensing and coordinated efforts may be needed to systematically reduce pharmacy-related barriers.
Keywords: Buprenorphine; Diversion; Naloxone; Opioid use disorder.
© 2022 The Authors. Published by Elsevier B.V.
Conflict of interest statement
No conflicts declared.
Figures
Similar articles
-
Independent community pharmacists' attitudes and intentions toward dispensing buprenorphine/naloxone for opioid use disorder.J Am Pharm Assoc (2003). 2023 Sep-Oct;63(5):1558-1565.e4. doi: 10.1016/j.japh.2023.06.010. Epub 2023 Jun 16. J Am Pharm Assoc (2003). 2023. PMID: 37331654
-
Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet. 2019 Feb 23;393(10173):778-790. doi: 10.1016/S0140-6736(18)32259-1. Epub 2019 Feb 18. Lancet. 2019. PMID: 30792007 Clinical Trial.
-
Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA.Addiction. 2021 Jun;116(6):1505-1511. doi: 10.1111/add.15314. Epub 2020 Nov 22. Addiction. 2021. PMID: 33140519
-
Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.Drug Alcohol Depend. 2014 Nov 1;144:1-11. doi: 10.1016/j.drugalcdep.2014.07.035. Epub 2014 Aug 19. Drug Alcohol Depend. 2014. PMID: 25179217 Free PMC article. Review.
-
Optimal dose of buprenorphine in opioid use disorder treatment: a review of pharmacodynamic and efficacy data.Drug Dev Ind Pharm. 2020 Jan;46(1):1-7. doi: 10.1080/03639045.2019.1706552. Epub 2020 Jan 8. Drug Dev Ind Pharm. 2020. PMID: 31914818
Cited by
-
Nurse Practitioner Work Environment and Rural Primary Care for Substance Use.J Nurse Pract. 2024 Oct;20(9):105152. doi: 10.1016/j.nurpra.2024.105152. Epub 2024 Jul 20. J Nurse Pract. 2024. PMID: 39131540
-
Mapping Buprenorphine Access at Philadelphia Pharmacies.J Addict Med. 2024 May-Jun 01;18(3):269-273. doi: 10.1097/ADM.0000000000001284. Epub 2024 Feb 12. J Addict Med. 2024. PMID: 38345212 Free PMC article.
-
Assessing suboxone access in community pharmacies: Secret shopper model.Explor Res Clin Soc Pharm. 2023 Nov 3;12:100356. doi: 10.1016/j.rcsop.2023.100356. eCollection 2023 Dec. Explor Res Clin Soc Pharm. 2023. PMID: 38023634 Free PMC article.
-
Community pharmacy attitudes and behaviors following a buprenorphine best practices dissemination.Ment Health Clin. 2025 Apr 4;15(2):43-50. doi: 10.9740/mhc.2025.04.043. eCollection 2025 Apr 1. Ment Health Clin. 2025. PMID: 40224513 Free PMC article.
-
Descriptive study: the novel "full spectrum people-with-opioid-use-disorder care model".Harm Reduct J. 2023 Apr 12;20(1):47. doi: 10.1186/s12954-023-00778-x. Harm Reduct J. 2023. PMID: 37046265 Free PMC article.
References
-
- Andrilla C.H.A., Patterson D.G. Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder. J. Rural Health. 2022;38(1):87–92. - PubMed
-
- Bakhireva L.N., Bautista A., Cano S., Shrestha S., Bachyrycz A.M., Cruz T.H. Barriers and facilitators to dispensing of intranasal naloxone by pharmacists. Subst. Abus. 2017;39(3):331–341. - PubMed
-
- Beetham T. Buprenorphine prior authorization removal: low hanging fruit in the opioid epidemic fight. Harv. Public Health Rev. 2019;25:1–5.
LinkOut - more resources
Full Text Sources